Polymalic acid-based nanobiopolymer compositions
Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.
1. A drug delivery composition for treating a cancer in a subject comprising:
a plurality of biologically active molecular modules comprising at least one module that targets a tumorigenic cell or a cancer cell, at least one module that inhibits synthesis or activity of a human epidermal growth factor receptor (HER) protein in the tumorigenic cell or the cancer cell, and at least one module for cytoplasmic delivery, wherein the at least one module that targets a tumorigenic cell or a cancer cell includes trastuzumab and an antibody specific for a tumor vasculature protein, and the at least one module that inhibits synthesis or activity of a human epidermal growth factor receptor (HER) protein is a Morpholino AON having a sequence selected from the group consisting of:
(SEQ ID NO: 1)
5′-AGGGAGCCGCAGCTTCATGTCTGTG-3′,
and
(SEQ ID NO: 2)
5′-CATGGTGCTCACTGCGGCTCCGGC-3′;
and
a polymalic acid-based molecular scaffold, wherein the molecular modules are covalently linked to the scaffold.
2. The drug delivery composition according to claim 1 , wherein the vasculature protein comprises a transferrin receptor protein.
3. The drug delivery composition according to claim 1 , wherein the antibody is anti-human.
4. The drug delivery composition according to claim 1 , wherein the antibody is selected from at least one of: rat anti-mouse, rat anti-human, mouse anti-human, rabbit anti-human and goat anti-human.
5. The drug delivery composition according to claim 1 , wherein the at least one module for cytoplasmic delivery comprises an endosome escape unit.
6. The drug delivery composition according to claim 5 , wherein the endosome escape unit comprises a leucine ethylester.
7. The drug delivery composition according to claim 1 , wherein the plurality of modules further comprises a polyethylene glycol.
8. The drug delivery composition according to claim 1 , wherein the polymalic acid-based molecular scaffold comprises a poly(β-L-malic) acid (PMLA).
9. The drug delivery composition according to claim 1 present in a unit dose effective for treatment of the cancer in the subject.
10. The drug delivery composition according to claim 9 , wherein the unit dose is at least one selected from the group consisting of: 1 μg/kg, 50 μg/kg, 100 μg/kg, 500 μg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg, 50 mg/kg, and 100 mg/kg.
11. The drug delivery composition according to claim 1 , wherein the cancer is at least one selected from the group consisting of: gastric, endometrial, salivary gland, lung, non-small cell lung, pancreatic, peritoneal, prostate, colorectal, breast, cervical, uterine, ovarian, brain, head and neck, testicular and teratoma cancers.
12. The drug delivery composition according to claim 11 , wherein the cancer is selected from the group consisting of a primary cancer and a metastatic cancer.
13. The drug delivery composition according to claim 11 , wherein the cancer comprises cells overexpressing a HER2/neu receptor protein.
14. A kit for treating a patient having a cancer comprising a drug delivery composition comprising a nanobiopolymeric conjugate of a scaffold comprising a polymalic acid (PMLA) and molecular modules comprising an antisense molecule that substantially inhibits synthesis or activity of a human epidermal growth factor receptor (HER) protein, wherein the antisense molecule comprises a Morpholino AON having a sequence complementary to a sequence contained in an mRNA transcript of HER2/neu protein, a molecular module to facilitate delivery of the antisense molecule to cytoplasm, at least one targeting antibody specific for the HER2/neu protein, at least one antibody specific for a tumor vasculature protein, and a molecular module that prolongs circulation of the composition, wherein the PMLA is covalently linked to the molecular modules, the at least one targeting antibody comprises trastuzumab and the Morpholino AON comprises a sequence selected from the group consisting of:
(SEQ ID NO: 1)
5′-AGGGAGCCGCAGCTTCATGTCTGTG-3′,
and
(SEQ ID NO: 2)
5′-CATGGTGCTCACTGCGGCTCCGGC-3′.
15. The kit according to claim 14 further comprising a pharmaceutically acceptable buffer.